Inhibition of kinase IKKβ suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6.
Animals
Cell Cycle Checkpoints
Cell Line, Tumor
Cell Proliferation
Cell Transformation, Viral
Compound Eye, Arthropod
/ abnormalities
DNA-Binding Proteins
/ metabolism
Drosophila
Drosophila Proteins
/ antagonists & inhibitors
Female
Humans
I-kappa B Kinase
/ antagonists & inhibitors
Nucleoside-Phosphate Kinase
/ metabolism
Oncogene Proteins, Viral
/ metabolism
PDZ Domains
Phosphorylation
Proteolysis
Ubiquitin-Protein Ligases
/ metabolism
Uterine Cervical Neoplasms
/ pathology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 01 2021
13 01 2021
Historique:
received:
18
12
2019
accepted:
15
12
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Human papillomavirus (HPV) is the leading cause of cervical cancer and has been implicated in several other cancer types including vaginal, vulvar, penile, and oropharyngeal cancers. Despite the recent availability of a vaccine, there are still over 310,000 deaths each year worldwide. Current treatments for HPV-mediated cancers show limited efficacy, and would benefit from improved understanding of disease mechanisms. Recently, we developed a Drosophila 'HPV 18 E6' model that displayed loss of cellular morphology and polarity, junctional disorganization, and degradation of the major E6 target Magi; we further provided evidence that mechanisms underlying HPV E6-induced cellular abnormalities are conserved between humans and flies. Here, we report a functional genetic screen of the Drosophila kinome that identified IKK[Formula: see text]-a regulator of NF-κB-as an enhancer of E6-induced cellular defects. We demonstrate that inhibition of IKK[Formula: see text] reduces Magi degradation and that this effect correlates with hyperphosphorylation of E6. Further, the reduction in IKK[Formula: see text] suppressed the cellular transformation caused by the cooperative action of HPVE6 and the oncogenic Ras. Finally, we demonstrate that the interaction between IKK[Formula: see text] and E6 is conserved in human cells: inhibition of IKK[Formula: see text] blocked the growth of cervical cancer cells, suggesting that IKK[Formula: see text] may serve as a novel therapeutic target for HPV-mediated cancers.
Identifiants
pubmed: 33441820
doi: 10.1038/s41598-020-80193-5
pii: 10.1038/s41598-020-80193-5
pmc: PMC7807017
doi:
Substances chimiques
DNA-Binding Proteins
0
Drosophila Proteins
0
E6 protein, Human papillomavirus type 18
0
Oncogene Proteins, Viral
0
UBE3A protein, human
EC 2.3.2.26
Ubiquitin-Protein Ligases
EC 2.3.2.27
I-kappa B Kinase
EC 2.7.11.10
IKBKB protein, human
EC 2.7.11.10
IKKbeta protein, Drosophila
EC 2.7.11.10
Nucleoside-Phosphate Kinase
EC 2.7.4.4
MAGI protein, Drosophila
EC 2.7.4.8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States
Références
Dis Model Mech. 2011 Jul;4(4):439-45
pubmed: 21669932
Semin Oncol Nurs. 2016 Aug;32(3):273-80
pubmed: 27539281
Oncogene. 2000 Nov 30;19(51):5884-91
pubmed: 11127819
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
J Virol. 1989 Oct;63(10):4417-21
pubmed: 2476573
Curr Opin Genet Dev. 2006 Feb;16(1):10-6
pubmed: 16359857
Am J Pathol. 2012 Feb;180(2):862-71
pubmed: 22138581
J Virol. 2011 Nov;85(22):11544-56
pubmed: 21775458
Cancer Sci. 2012 Jan;103(1):100-6
pubmed: 21951590
Oncogene. 2014 Feb 27;33(9):1135-47
pubmed: 23455325
Dev Dyn. 2012 Jan;241(1):40-56
pubmed: 21932322
Blood. 2005 Mar 15;105(6):2324-31
pubmed: 15561889
Front Genet. 2019 Mar 01;10:51
pubmed: 30881374
Cytokine. 2016 Jul;83:85-91
pubmed: 27064455
Cell. 2004 Apr 16;117(2):225-37
pubmed: 15084260
J Cell Mol Med. 2010 Mar;14(3):687-98
pubmed: 19243472
Carcinogenesis. 2010 Nov;31(11):1905-12
pubmed: 20819779
Int Arch Allergy Immunol. 2009;148(3):186-98
pubmed: 18849610
Oncogene. 2000 Feb 10;19(6):719-25
pubmed: 10698489
Oncol Rep. 2019 Aug 08;:
pubmed: 31524267
Cell. 1993 Nov 5;75(3):495-505
pubmed: 8221889
Curr Top Dev Biol. 2009;89:115-35
pubmed: 19737644
Oncogene. 2004 May 13;23(22):3972-9
pubmed: 15077191
Biomed Res Int. 2014;2014:574659
pubmed: 25478571
J Exp Med. 2013 Jul 1;210(7):1369-87
pubmed: 23752229
Mol Cell Biol. 2000 Nov;20(21):8244-53
pubmed: 11027293
Cell Growth Differ. 1994 Jun;5(6):667-75
pubmed: 7522035
Hum Mol Genet. 2006 Sep 15;15(18):2825-35
pubmed: 16905559
Genes Dev. 2001 Sep 15;15(18):2321-42
pubmed: 11562344
J Virol. 2011 Feb;85(4):1757-64
pubmed: 21123374
Exp Cell Res. 2002 May 1;275(2):155-70
pubmed: 11969287
Int J Cancer. 1993 Jan 2;53(1):22-8
pubmed: 8380055
Sci Rep. 2019 Jul 10;9(1):10003
pubmed: 31292507
J Virol. 2006 Jun;80(11):5301-7
pubmed: 16699010
Biochem Biophys Res Commun. 2014 Sep 5;451(4):548-55
pubmed: 25117438
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):553-60
pubmed: 23549399
Oral Oncol. 2014 May;50(5):468-77
pubmed: 24582884
Mol Cell Biol. 2011 Jun;31(11):2210-26
pubmed: 21482671
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11612-6
pubmed: 9326658
Open Biol. 2017 Aug;7(8):
pubmed: 28855394
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Annu Rev Immunol. 2009;27:693-733
pubmed: 19302050
Oncogene. 2011 Sep 29;30(39):4063-6
pubmed: 21499298
J Virol. 2015 Feb;89(3):1579-86
pubmed: 25410862
J Virol. 2003 Jun;77(12):6957-64
pubmed: 12768014
J Gastroenterol. 2009;44(9):935-43
pubmed: 19557302
Leukemia. 2006 Jan;20(1):61-7
pubmed: 16270044
Int J Cancer. 2011 Feb 15;128(4):879-86
pubmed: 20473890
Science. 1989 Feb 17;243(4893):934-7
pubmed: 2537532
J Virol. 2008 Mar;82(5):2493-500
pubmed: 18160445
Int J Cancer. 2010 Mar 1;126(5):1263-74
pubmed: 19728335
Nat Rev Mol Cell Biol. 2016 Sep;17(9):564-80
pubmed: 27353478
Transl Cancer Res. 2012 Aug;1(2):100-108
pubmed: 22953243
Cancer Treat Rev. 2008 Nov;34(7):603-13
pubmed: 18657909
J Gen Virol. 2018 May;99(5):667-675
pubmed: 29595418
J Med Dent Sci. 2008 Mar;55(1):49-59
pubmed: 19845150
Hum Vaccin Immunother. 2016 Jun 2;12(6):1418-29
pubmed: 26835746
Cell. 1990 Dec 21;63(6):1129-36
pubmed: 2175676
Cancer Lett. 1996 Nov 12;108(1):15-23
pubmed: 8950204
Immunol Res. 1999;19(2-3):183-9
pubmed: 10493172
Lancet Oncol. 2015 May;16(5):e217-25
pubmed: 25943066
Semin Immunol. 2000 Feb;12(1):85-98
pubmed: 10723801
Cytokine. 2011 Mar;53(3):282-5
pubmed: 21167737
Annu Rev Immunol. 1998;16:225-60
pubmed: 9597130
Blood Cancer J. 2011 Mar;1(3):e12
pubmed: 22829125
Cancer Res. 2010 May 15;70(10):4005-14
pubmed: 20424119
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2629-34
pubmed: 19196987
PLoS Pathog. 2016 Aug 18;12(8):e1005789
pubmed: 27537218
J Biol Chem. 2004 Aug 27;279(35):36287-92
pubmed: 15192088
Invest Ophthalmol Vis Sci. 2014 Sep 09;55(10):6365-73
pubmed: 25205865
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Oncogene. 2006 Jan 19;25(3):387-98
pubmed: 16170348
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):950-60
pubmed: 16467110
BMC Biochem. 2008 Oct 21;9 Suppl 1:S4
pubmed: 19007434
Arch Biochem Biophys. 2015 May 1;573:52-8
pubmed: 25797437
J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71
pubmed: 7658497
Front Immunol. 2014 Sep 24;5:464
pubmed: 25309546
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1954-9
pubmed: 20647411
Mol Cell Endocrinol. 2008 Oct 10;293(1-2):25-31
pubmed: 18374475
Medchemcomm. 2019 Apr 30;10(6):867-879
pubmed: 31303984
PLoS One. 2016 Apr 13;11(4):e0153259
pubmed: 27074039
Science. 1990 Apr 6;248(4951):76-9
pubmed: 2157286
Genesis. 2002 Sep-Oct;34(1-2):1-15
pubmed: 12324939
J Virol. 2013 Feb;87(3):1586-95
pubmed: 23175360
G3 (Bethesda). 2017 Aug 7;7(8):2427-2438
pubmed: 28620086